169 results on '"Eisenhauer, Elizabeth A."'
Search Results
2. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs
3. Common Sense Oncology: outcomes that matter
4. Patients’ attitudes and preferences toward delayed disease progression in the absence of improved survival
5. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
6. Characterizing Variability in Lung Cancer Outcomes and Influence of a Lung Diagnostic Assessment Program in Southeastern Ontario, Canada
7. Thoughts on Writing High-Quality Review Articles
8. Characterizing Regional Variability in Lung Cancer Outcomes across Ontario—A Population-Based Analysis
9. Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply
10. FACTORS ASSOCIATED WITH PATIENT MANAGEMENT THROUGH A LUNG DIAGNOSTIC ASSESSMENT PROGRAM IN SOUTHEASTERN ONTARIO, CANADA
11. A flexible movement model for partially migrating species
12. Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class
13. The Time Toxicity of Cancer Treatment
14. DR PHILIP H. PHENIX'S CONTRIBUTIONS HAVE BEEN OVERLOOKED
15. Perspective on Cancer Control: Whither the Tobacco Endgame for Canada?
16. Progression-free survival: it is time for a new name
17. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment
18. Writing the Protocol
19. Basics of Phase I Design
20. Introduction
21. Process, Pitfalls, and Logistics of Phase I Trials
22. Ethical Issues in First-in-Human Phase I Cancer Trials
23. Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?
24. CHARACTERIZING REGIONAL VARIABILITY IN HEALTH RESOURCE UTILIZATION DURING THE DIAGNOSTIC PHASE OF LUNG CANCER ACROSS ONTARIO: A POPULATION-BASED ANALYSIS
25. CHARACTERIZING REGIONAL VARIABILITY IN LUNG CANCER OUTCOMES ACROSS ONTARIO: A POPULATION-BASED ANALYSIS
26. Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity—Reply
27. Women’s Choices Regarding Use of Their Newborns’ Residual Dried Blood Samples in Research
28. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
29. Medical students need artificial intelligence and machine learning training
30. Covid-19 Pandemic—An Opportunity to Reduce and Eliminate Low-Value Practices in Oncology?
31. Machine learning for modeling animal movement
32. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016
33. The European Organisation for Research and Treatment of Cancer, State of Science in radiation oncology and priorities for clinical trials meeting report
34. A lattice and random intermediate point sampling design for animal movement
35. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer
36. CLINICAL TRIAL DESIGNS FOR CYTOSTATIC AGENTS AND AGENTS DIRECTED AT NOVEL MOLECULAR TARGETS
37. CONTRIBUTORS
38. Mothers' Decisions About Donating Newborns' Blood Spots for Research
39. Imaging progression-free survival: How much does it matter to patients?
40. Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma
41. Participants’ Understanding of Informed Consent for Biobanking: A Systematic Review
42. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
43. Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use.
44. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).
45. OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC).
46. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17
47. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
48. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
49. Religious Values and Biobanking Decisions: An Integrative Review
50. Informed Consent and the Use of Biospecimens in Research
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.